Recently, the U.S. Food and Drug Administration (FDA) officially approved Turoctocog Alfa Pegol (brand name: Esperoct®), a new long-acting Factor VIII drug developed by Novo Nordisk, for the treatment of Hemophilia A. This groundbreaking drug…
Mavacamten Capsules, a revolutionary drug for treating obstructive hypertrophic cardiomyopathy (HCM), is gaining attention due to its ability to reduce left ventricular outflow tract (LVOT) obstruction. In this article, DengYue will explore its mechanism of…
February 25, 2025 – In an exciting advancement in immunotherapy, the combination of Iparomlimab and Tuvonralimab injection is demonstrating significant efficacy in the treatment of multiple cancers and autoimmune diseases, according to recent clinical trial…
Janagliflozin, also known as Ganagliflozin Proline Tablets, marketed under the brand name HuiYouJing, is an innovative drug that has gained attention for its effectiveness in managing type 2 diabetes. As a member of the SGLT2…
On October 11, 2024, Junshi Biosciences announced that its self-developed recombinant humanized anti-PCSK9 monoclonal antibody injection, Ongericimab (brand name: JUNSHID®). Has been approved by the National Medical Products Administration (NMPA) for the treatment of adult…
In the fight against severe and chronic auto-inflammatory diseases, Rilonacept Injection has emerged as a groundbreaking treatment, offering hope for patients battling debilitating conditions like Cryopyrin-Associated Periodic Syndromes (CAPS) and Systemic Juvenile Idiopathic Arthritis (SJIA).…
February 2025 – In a groundbreaking advancement in the treatment of platinum-resistant ovarian cancer, the investigational drug Mirvetuximab Soravtansine-Gynx has emerged as a potential game-changer. This novel therapy, developed by ImmunoGen, combines targeted monoclonal antibody…
February 2025 — In a significant advancement in the treatment of certain aggressive cancers, Sacituzumab Tirumotecan for Injection (brand name Trodelvy) has garnered attention for its innovative approach to fighting metastatic cancers. Approved by the…
February 2025 — In a significant breakthrough for cancer treatment, Loncastuximab Tesirine-lpyl (brand name Zynlonta) is rapidly gaining attention as a promising new option for patients with relapsed or refractory large B-cell lymphoma (LBCL). Recently…
In the rapidly advancing world of cancer treatment, Lunsumio(Mosunetuzumab) has emerged as a promising new therapy, offering hope to patients with certain types of B-cell non-Hodgkin lymphoma (NHL). This cutting-edge bispecific monoclonal antibody is poised…
In the ever-evolving landscape of oncology, a promising new drug, Zolbetuximab-Clzb for Injection, has made headlines as it advances through clinical trials and regulatory processes. This innovative monoclonal antibody is being developed as a potential…
In recent years, Vindesine Sulfate For Injection, as a chemotherapeutic drug, has demonstrated remarkable efficacy in the treatment of a variety of malignant tumors. As a paclitaxel, Vindesine plays an inhibitory role in tumor growth…
